Filter by Priority

Specify Publication

TitlePublication typePriorityDate
Europe's Life Sciences industry reacts to agreed Brexit transition periodPress releaseValue of Healthcare biotech23.03.2018
European health community issues key questions Article 50 negotiations must answer for patients and public healthPress releaseValue of Healthcare biotech09.03.2018
Joint Life Science Industry Policy Paper on the Potential Impact of BrexitPosition papersValue of Healthcare biotech14.12.2017
Launching the Joint Life Science Industry Policy Paper on the Potential Impact of BrexitPress releaseValue of Healthcare biotech14.12.2017
EC launches biosimilar medicines Q&A for patients in 23 languagesPress releaseBiosimilars29.11.2017
Industry calls on UK+EU27 to safeguard patients’ access to medicines with transition + cooperation agreement post-BrexitPress releaseValue of Healthcare biotech28.11.2017
From Patent to Patient: The importance of IP rewards and incentivesReportValue of Healthcare biotech23.11.2017
EuropaBio statement regarding the re-location of the EMA to AmsterdamPress releaseValue of Healthcare biotech20.11.2017
Joint press release on ATMPs and GMOs in EuropePress releaseAdvanced-Therapy Medicinal Products27.09.2017
EuropaBio Statement on EU Ombudsman inquiry into EMA pre‐submission activitiesPress releaseValue of Healthcare biotech24.07.2017
Joint Trade Association Letter on BrexitValue of Healthcare biotech13.07.2017
EuropaBio's Biosimilar SmPC RecommendationsPosition papersBiosimilars06.06.2017
EuropaBio launches recommendations to enhance transparency of biosimilar labelsPress releaseBiosimilars06.06.2017
Industry Welcomes 3rd EC Workshop on BiosimilarsPress releaseBiosimilars05.05.2017
How healthcare biotech works and benefits patients and societyVideoValue of Healthcare biotech05.05.2017
How Healthcare Biotech Benefits Europe’s Economy and InnovationVideoValue of Healthcare biotech30.03.2017
How does Healthcare Biotech Benefit Europe?VideoValue of Healthcare biotech16.03.2017
Statement on the European Parliament report on improving access to medicinesPress releaseValue of Healthcare biotech03.03.2017
EFPIA, EUCOPE and EuropaBio Statement on EC Off-Label Use StudyPress releaseValue of Healthcare biotech02.03.2017
"Buying Innovative" in the Healthcare Biotech Market in EuropeReportPublic procurement10.02.2017
EC Initiative Improves Information for Patients on BiosimilarsPress releaseBiosimilars23.01.2017
Scientific data and clinical decision making – the NOR-SWITCH StudyPress releaseBiosimilars20.10.2016
The Evolution of Biotechnology: the arrival of biosimilarsVideoBiosimilars12.07.2016
Industry Welcomes the EC Workshop on the Uptake of BiosimilarsPress releaseBiosimilars20.06.2016
EuropaBio supports UK BIA call to review IP court decision in the USPosition papersPublic procurement21.04.2016
Results from the first ever European biosimilars labelling surveyPress releaseBiosimilars19.04.2016
EU physicians prefer greater detail in the labelling of biosimilarsPress releaseBiosimilars19.04.2016
Effects of biosimilar competition on price and volume in EuropePress releaseBiosimilars16.12.2015
Welcoming EC Commitment to Off-Patent Biologics MarketPress releaseValue of Healthcare biotech06.10.2015
Swift EU action needed to ensure biotech sector stays competitivePress releaseValue of Healthcare biotech30.09.2015
50 years of EU Pharma LegislationPress releaseValue of Healthcare biotech28.09.2015
Industry complaint against French off-label use lawPress releaseValue of Healthcare biotech31.08.2015
Access to personalised medicine is still limited in EuropePress releasePersonalised medecine09.07.2015
Public procurement of biologic medicinesPress releasePublic procurement29.06.2015
Public procurement of biologic medicinesPosition papersPublic procurement29.06.2015
Industry concern over EU science budget cutsPress releaseValue of Healthcare biotech03.06.2015
EuropaBio and EFPIA celebrate the 15th anniversary of the EU Orphan Medicines RegulationReportOrphan medicines26.05.2015
Regulatory and HTA scientific advice for SMEsReportHealth Technology Assessment17.03.2015
Biosimilars: What's in a name?VideoBiosimilars06.01.2015
ASBM presented results of European physician survey at EuropaBio – ASEBIO MeetingPress releaseBiosimilars27.11.2014
EuropaBio launches guide and position paper on biosimilarsPress releaseBiosimilars06.10.2014
Guide on Biosimilars in EuropePosition papersBiosimilars06.10.2014
EuropaBio Position Paper on Biosimilars in EuropePosition papersBiosimilars06.10.2014
EMA policy on clinical trial data publicationPress releaseValue of Healthcare biotech03.10.2014
A wake up call for personalised medicine in EuropePress releasePersonalised medecine24.09.2014
Realising the potential of personalised medicine in EuropeWhite paperPersonalised medecine24.09.2014
EuropaBio calls for EMA action on labeling of biosimilarsPress releaseBiosimilars18.09.2014
EuropaBio Statement on Labelling of BiosimilarsPress releaseBiosimilars15.09.2014
Our 2020 VisionPosition papersOrphan medicines11.09.2014
Development process of Orphan Medicinal ProductsReportOrphan medicines11.09.2014
Valuing Healthcare Biotechnology in EuropePosition papersValue of Healthcare biotech22.07.2014
Pan-European survey calls for a shift in policy for biosimilarsPress releaseBiosimilars18.04.2014
Stem-Cell Treatment for Blindness Moving Through Patient TestingPress releaseAdvanced-Therapy Medicinal Products16.04.2014
Irish and UK scientists use stem cells to grow red blood cellsPress releaseAdvanced-Therapy Medicinal Products15.04.2014
Funding the EU pharmacovigilance systemPress releaseValue of Healthcare biotech21.02.2014
Draft EU Clinical Trials Regulation lacks ambitionPress releaseValue of Healthcare biotech20.12.2013
The value of industry involvement in HTAPosition papersHealth Technology Assessment07.12.2013
Trialogue forgets importance of competitive clinical trial authorisation timelinesPress releaseValue of Healthcare biotech27.11.2013
EMA strengthens the biosimilars pathway in EuropePress releaseBiosimilars05.11.2013
EuropaBio joins the Alliance for Safe Biologic Medicines Press releaseBiosimilars27.06.2013
Access to OMPs remains unfinished despite MOCA ReportPress releaseOrphan medicines08.05.2013
EC launches Biosimilars Consensus Information DocumentPress releaseBiosimilars19.04.2013
Rare diseases go beyond borders – so should research and treatmentPress releaseOrphan medicines28.02.2013
Biotech products and HTAPosition papersHealth Technology Assessment13.02.2012
Development process of Orphan MedicinesReportOrphan medicines01.06.2011
EuropaBio Healthcare Manifesto 2011 - 2012Position papersValue of Healthcare biotech13.01.2011
Get the facts : Patient-centred healthcare systems in Europe: what role for biotech?VideoValue of Healthcare biotech06.11.2009
Christofer Fjellner, MEP, discusses patient-centred healthcare systems in EuropeVideoValue of Healthcare biotech03.11.2009